As per the Atmanirbhar Bharat 3.0 Mission, COVID Suraksha was declared by the Government of India to quicken the development and creation of a native COVID-19 Vaccine. Department of Biotechnology, GOI, and Biotechnology Industry Research Assistance Council (BIRAC), New Delhi, has implemented this.

To augment the potential for indigenous creation of Covaxin under the mission, the Department of Biotechnology, GOI in April 2021 supplied financial aid as a grant to vaccine production centers for improved production capabilities, which can be expected to achieve over ten crore doses per month from September 2021 onwards.

As a part of the augmentation program, Bharat Biotech Limited’s abilities, Hyderabad, and other public business manufactures are being updated with infrastructure and technologies. Financial support has been provided as a grant in GOI to the tune of approximately Rs. 65 Crores to Bharat Biotech‘s new Bangalore facility has been repurposed to grow the potential of vaccine manufacturing.

The following three public sector undertaking are being encouraged to boost the capacity of Covaxin vaccine manufacturing –

1. Haffkine Biopharmaceutical Corporation Ltd, Mumbai-a State PSE beneath State Govt of Maharashtra – Fiscal support of Rs. Sixty-five crores as grant in GoI have been supplied with this facility to be ready for production. The center will have a capacity of 20 million doses each month, once usable.

2. Indian Immunologicals Limited (IIL), Hyderabad – A center under National Dairy Development Board has been supplied a supply of Rs. 60 crores and

3. Bharat Immunologicals and Biologicals Limited (BIBCOL), Bulandshahr – a CPSE under the Department of Biotechnology, Government of India has been supported with a grant of Rs. 30 crores to prepare their center to supply 10-15 million doses each month.

Further, Gujarat Biotechnology Research Centre, Department of Science and Technology Govt. of Gujarat, along with Hester Biosciences and OmniBRx, has also firmed up its negotiations with Bharat Biotech scale up the COVAXIN technology and also generate a minimum of 20 million doses each month. Technology transfer agreements have been finalized with all manufacturers.